Country, language and currency
- Social bookmarks:
- Testimonials
-
Read more »
Our billing is certified by:
-
- Addition Of Velcade Improves Thalidomide-Dexamethasone Consolidation Therapy ... - The Myeloma Beacon
- Addition Of Velcade Improves Thalidomide-Dexamethasone Consolidation Therapy
- Me vs. MM: Agent D - The Myeloma Beacon
- Me vs
- Celgene announces three phase III Revlimid trials in newly diagnosed MM patients - pharmabiz.com
- Celgene announces three phase III Revlimid trials in newly diagnosed MM patientspharmabiz
- Len-Dex Induction Delays Progression in Smoldering Myeloma - Clinical Oncology News
- Clinical Oncology NewsLen-Dex Induction Delays Progression in Smoldering MyelomaClinical Oncology NewsSan Diego—Patients with high-risk asymptomatic multiple myeloma, characterized as smoldering multiple myeloma (SMM), can delay their time to progression with an induction regimen of lenalidomide and dexamethasone (Len-Dex), according to the results of
- Chemo combination promising for multiple myeloma - Medical Xpress
- Chemo combination promising for multiple myelomaMedical XpressFor patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according to a study published online April 30 in
